Schizophrenia Biomarkers: Blood Transcriptome Suggests Two Molecular Subtypes
2024

Schizophrenia Biomarkers: Blood Transcriptome Suggests Two Molecular Subtypes

Sample size: 398 publication 10 minutes Evidence: moderate

Author Information

Author(s): Dor Herut, Hertzberg Libi

Primary Institution: Tel Aviv University

Hypothesis

Can blood transcriptomes help identify molecular subtypes of schizophrenia?

Conclusion

The study identified two molecular subtypes of schizophrenia based on blood transcriptome analysis, which may aid in understanding the disease and developing personalized treatments.

Supporting Evidence

  • Patients with schizophrenia can be clustered into two molecular subtypes based on blood transcriptome analysis.
  • One subtype shows gene expression patterns similar to healthy controls, while the other differs significantly.
  • Ribosomal and ubiquitin-proteasome system genes were found to be enriched in the clustering analysis.

Takeaway

Scientists found two different types of schizophrenia by looking at blood samples, which could help doctors treat patients better.

Methodology

The study analyzed blood transcriptomes from 398 samples using unsupervised machine learning to identify molecular subtypes.

Potential Biases

Potential confounding factors such as age, sex, and antipsychotic treatment may affect gene expression results.

Limitations

The study's cross-sectional design limits causal inferences, and gene expression may be influenced by external factors like infection and medication.

Participant Demographics

The study included 212 patients with schizophrenia and 186 healthy controls.

Statistical Information

P-Value

0.039

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1007/s12017-024-08817-x

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication